New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug, OMTX705, alone or with standard immunotherapy drugs (pembrolizumab or tislelizumab) in 150 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the best dose, while also l…
Phase: PHASE1 • Sponsor: Oncomatryx Biopharma S.L. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC